Production (Stage)
ANI Pharmaceuticals, Inc.
ANIP
$57.79
$0.520.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 197.12M | 190.57M | 148.33M | 138.04M | 137.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 197.12M | 190.57M | 148.33M | 138.04M | 137.43M |
| Cost of Revenue | 73.04M | 80.28M | 63.08M | 57.70M | 49.16M |
| Gross Profit | 124.09M | 110.29M | 85.26M | 80.34M | 88.27M |
| SG&A Expenses | 75.63M | 69.52M | 70.28M | 49.42M | 48.02M |
| Depreciation & Amortization | 22.89M | 22.60M | 15.75M | 14.70M | 14.69M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 182.12M | 189.05M | 159.23M | 129.11M | 122.38M |
| Operating Income | 15.00M | 1.53M | -10.89M | 8.93M | 15.06M |
| Income Before Tax | 19.99M | -13.76M | -31.50M | -2.29M | 25.34M |
| Income Tax Expenses | 4.31M | -3.49M | -7.33M | 0.00 | 7.13M |
| Earnings from Continuing Operations | 15.68M | -10.28M | -24.17M | -2.29M | 18.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.68M | -10.28M | -24.17M | -2.29M | 18.21M |
| EBIT | 15.00M | 1.53M | -10.89M | 8.93M | 15.06M |
| EBITDA | 37.89M | 24.13M | 4.85M | 23.63M | 29.74M |
| EPS Basic | 0.70 | -0.55 | -1.27 | -0.05 | 0.84 |
| Normalized Basic EPS | 0.31 | -0.19 | -0.51 | 0.14 | 0.34 |
| EPS Diluted | 0.69 | -0.55 | -1.27 | -0.05 | 0.83 |
| Normalized Diluted EPS | 0.30 | -0.19 | -0.51 | 0.14 | 0.34 |
| Average Basic Shares Outstanding | 19.61M | 19.45M | 19.40M | 19.32M | 19.10M |
| Average Diluted Shares Outstanding | 20.05M | 19.45M | 19.40M | 19.32M | 19.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 2.59% | -3.95% | -1.68% | -17.80% | 2.23% |